Fig. 5.

Targeting the tumor draining lymph node (tDLN) produces an abscopal effect; tumor antigens (cellular vaccine) in the absence of tumor/tDLN microenvironment are not sufficient to generate a full anti-tumor response. a Using a single tumor A20 model, mice were treated with four biweekly doses of the triple combination αCD137, αOX40, and αCTLA4 at a dose of 10 µg each delivered IT, or subcutaneous (SC) peri-tumoral, ipsilateral abdominal wall (targeting the tDNL) or contralateral abdominal wall (targeting the non-tDLN). A cellular vaccine (irradiated A20 cells plus the triple combination 10 µg) was delivered on the contralateral wall (SC) × four biweekly doses. Tumor growth measured by caliper (b–g) and survival curve (h). ‘*’ denotes p < .05 Student’s t test (tumor growth) or Mantel–Cox test (survival). n = 10/group